MX350582B - Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. - Google Patents
Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante.Info
- Publication number
- MX350582B MX350582B MX2013014543A MX2013014543A MX350582B MX 350582 B MX350582 B MX 350582B MX 2013014543 A MX2013014543 A MX 2013014543A MX 2013014543 A MX2013014543 A MX 2013014543A MX 350582 B MX350582 B MX 350582B
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- treatment
- recombinant vwf
- coagulation disease
- disease
- Prior art date
Links
- 230000015271 coagulation Effects 0.000 title abstract 2
- 238000005345 coagulation Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 208000027276 Von Willebrand disease Diseases 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495884P | 2011-06-10 | 2011-06-10 | |
| US201161511901P | 2011-07-26 | 2011-07-26 | |
| US201161523790P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/041957 WO2012171031A1 (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014543A MX2013014543A (es) | 2014-06-11 |
| MX350582B true MX350582B (es) | 2017-09-11 |
Family
ID=46321496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014543A MX350582B (es) | 2011-06-10 | 2012-06-11 | Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. |
| MX2020000083A MX2020000083A (es) | 2011-06-10 | 2013-12-10 | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000083A MX2020000083A (es) | 2011-06-10 | 2013-12-10 | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9272021B2 (enExample) |
| EP (3) | EP3412305B1 (enExample) |
| JP (3) | JP6347468B2 (enExample) |
| KR (3) | KR101969515B1 (enExample) |
| CN (3) | CN108210889A (enExample) |
| AR (1) | AR086904A1 (enExample) |
| AU (5) | AU2012267458A1 (enExample) |
| CA (1) | CA2838845C (enExample) |
| DK (3) | DK3412305T3 (enExample) |
| ES (3) | ES2976169T3 (enExample) |
| FI (1) | FI3858375T3 (enExample) |
| HK (1) | HK1257436A1 (enExample) |
| HR (1) | HRP20180962T1 (enExample) |
| HU (1) | HUE039317T2 (enExample) |
| LT (1) | LT2717905T (enExample) |
| MX (2) | MX350582B (enExample) |
| PL (3) | PL2717905T3 (enExample) |
| PT (3) | PT3412305T (enExample) |
| RU (2) | RU2628537C2 (enExample) |
| SG (2) | SG10202002591QA (enExample) |
| SI (1) | SI2717905T1 (enExample) |
| TR (1) | TR201808823T4 (enExample) |
| WO (1) | WO2012171031A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3412305T3 (da) * | 2011-06-10 | 2021-03-01 | Baxalta GmbH | Behandling af koagulationssygdom ved administration af rekombinant vwf |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| CA3020346A1 (en) | 2016-04-15 | 2017-10-19 | Baxalta Incorporated | Method and apparatus for providing a pharmacokinetic drug dosing regimen |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| KR102788331B1 (ko) | 2017-07-07 | 2025-03-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료 |
| EP4424366A3 (en) | 2017-07-07 | 2024-12-04 | Takeda Pharmaceutical Company Limited | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
| EP3749696A1 (en) | 2018-02-06 | 2020-12-16 | Ablynx N.V. | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| IL277464B1 (en) * | 2018-03-21 | 2026-04-01 | Baxalta Inc | Separation of VWF and VWF propeptide using chromatographic methods |
| EA202192140A1 (ru) * | 2019-02-01 | 2021-12-15 | Такеда Фармасьютикал Компани Лимитед | СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) |
| CN114929260A (zh) * | 2019-09-11 | 2022-08-19 | 武田药品工业株式会社 | 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法 |
| CN115335074A (zh) * | 2020-02-04 | 2022-11-11 | 武田药品工业株式会社 | 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多 |
| TW202237149A (zh) * | 2020-11-24 | 2022-10-01 | 美商邦德治療公司 | 用於治療出血性障礙之組成物及方法 |
| WO2024124136A1 (en) * | 2022-12-09 | 2024-06-13 | Vega Therapeutics, Inc. | Von willebrand disease animal models |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4638028A (en) | 1985-04-08 | 1987-01-20 | Goodyear Tire & Rubber Company | Rubber polymerases and methods for their production and use |
| EP0218692A4 (en) | 1985-04-11 | 1988-03-22 | Childrens Medical Center | VON WILLEBRAND FACTOR. |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT406373B (de) * | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| US6864403B1 (en) | 1998-10-15 | 2005-03-08 | E. I. Du Pont De Nemours And Company | Plant protein disulfide isomerases |
| US20040014657A1 (en) * | 2001-11-05 | 2004-01-22 | Jan Ohrstrom | Use of blood coagulation factor XIII for treating haemophilia A |
| WO2005012354A1 (en) * | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CN101163506B (zh) * | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| JP2010529155A (ja) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用 |
| KR20100095441A (ko) | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법 |
| JP2009127455A (ja) | 2007-11-20 | 2009-06-11 | Bando Kiko Co Ltd | 往復動エンジン |
| SG187410A1 (en) * | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| PL2291523T3 (pl) * | 2008-06-24 | 2015-05-29 | Csl Behring Gmbh | Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo |
| EP2349314B1 (en) * | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| AU2010279463A1 (en) * | 2009-08-04 | 2012-03-01 | Baxter Healthcare S.A. | Transgenic mouse knockout for FVIII and VWF - model of hemophilia A |
| WO2012006594A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | Method of producing recombinant adamts13 in cell culture |
| US20120006800A1 (en) | 2010-07-09 | 2012-01-12 | Illinois Tool Works Inc. | Weld bead feature communication systems and devices |
| DK3412305T3 (da) * | 2011-06-10 | 2021-03-01 | Baxalta GmbH | Behandling af koagulationssygdom ved administration af rekombinant vwf |
-
2012
- 2012-06-11 DK DK18173179.5T patent/DK3412305T3/da active
- 2012-06-11 CN CN201810079423.5A patent/CN108210889A/zh active Pending
- 2012-06-11 HU HUE12728919A patent/HUE039317T2/hu unknown
- 2012-06-11 ES ES20216368T patent/ES2976169T3/es active Active
- 2012-06-11 PT PT181731795T patent/PT3412305T/pt unknown
- 2012-06-11 PL PL12728919T patent/PL2717905T3/pl unknown
- 2012-06-11 CN CN201611071108.5A patent/CN107412743B/zh active Active
- 2012-06-11 RU RU2014100107A patent/RU2628537C2/ru active
- 2012-06-11 FI FIEP20216368.9T patent/FI3858375T3/fi active
- 2012-06-11 CA CA2838845A patent/CA2838845C/en active Active
- 2012-06-11 US US13/493,926 patent/US9272021B2/en active Active
- 2012-06-11 HR HRP20180962TT patent/HRP20180962T1/hr unknown
- 2012-06-11 KR KR1020147000709A patent/KR101969515B1/ko active Active
- 2012-06-11 DK DK20216368.9T patent/DK3858375T3/da active
- 2012-06-11 WO PCT/US2012/041957 patent/WO2012171031A1/en not_active Ceased
- 2012-06-11 KR KR1020197010327A patent/KR20190041032A/ko not_active Ceased
- 2012-06-11 KR KR1020207020667A patent/KR102319868B1/ko active Active
- 2012-06-11 AR ARP120102073A patent/AR086904A1/es not_active Application Discontinuation
- 2012-06-11 CN CN201280038870.7A patent/CN103732244A/zh active Pending
- 2012-06-11 AU AU2012267458A patent/AU2012267458A1/en not_active Abandoned
- 2012-06-11 PL PL20216368.9T patent/PL3858375T3/pl unknown
- 2012-06-11 ES ES12728919.7T patent/ES2682249T3/es active Active
- 2012-06-11 SG SG10202002591QA patent/SG10202002591QA/en unknown
- 2012-06-11 ES ES18173179T patent/ES2860450T3/es active Active
- 2012-06-11 SI SI201231321T patent/SI2717905T1/sl unknown
- 2012-06-11 PL PL18173179T patent/PL3412305T3/pl unknown
- 2012-06-11 EP EP18173179.5A patent/EP3412305B1/en active Active
- 2012-06-11 DK DK12728919.7T patent/DK2717905T3/en active
- 2012-06-11 JP JP2014514934A patent/JP6347468B2/ja active Active
- 2012-06-11 EP EP12728919.7A patent/EP2717905B1/en active Active
- 2012-06-11 TR TR2018/08823T patent/TR201808823T4/tr unknown
- 2012-06-11 LT LTEP12728919.7T patent/LT2717905T/lt unknown
- 2012-06-11 EP EP20216368.9A patent/EP3858375B1/en active Active
- 2012-06-11 PT PT202163689T patent/PT3858375T/pt unknown
- 2012-06-11 PT PT127289197T patent/PT2717905T/pt unknown
- 2012-06-11 MX MX2013014543A patent/MX350582B/es active IP Right Grant
- 2012-06-11 SG SG10201604684WA patent/SG10201604684WA/en unknown
- 2012-06-11 RU RU2017102679A patent/RU2680402C2/ru active
-
2013
- 2013-12-10 MX MX2020000083A patent/MX2020000083A/es unknown
-
2015
- 2015-12-30 US US14/985,212 patent/US20160184403A1/en not_active Abandoned
-
2016
- 2016-04-13 AU AU2016202299A patent/AU2016202299B2/en active Active
- 2016-07-12 JP JP2016137381A patent/JP6527114B2/ja active Active
-
2017
- 2017-07-20 AU AU2017206235A patent/AU2017206235B2/en active Active
-
2018
- 2018-12-27 HK HK18116648.2A patent/HK1257436A1/zh unknown
- 2018-12-28 JP JP2018246475A patent/JP2019048892A/ja active Pending
-
2020
- 2020-01-02 AU AU2020200026A patent/AU2020200026A1/en not_active Abandoned
-
2022
- 2022-03-04 AU AU2022201518A patent/AU2022201518B2/en active Active
-
2025
- 2025-02-28 US US19/067,628 patent/US20250387455A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| GT201400055A (es) | Proteínas de fusión para tratar trastornos metabolicos | |
| NZ711373A (en) | Fragments of p97 and uses thereof | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EP4374873A3 (en) | Methods for treating or preventing opthalmological conditions | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| MX366134B (es) | Angiotensina en el tratamiento de condiciones cerebrales. | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| MX2017014503A (es) | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. | |
| MX2013007995A (es) | Peptidos derivados de lactoferrina humana y su uso. | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| EA201500363A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
| EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
| GB201201753D0 (en) | Therapeutic agents with improved fibrinogen binding | |
| PT3648788T (pt) | Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante | |
| MX373466B (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| WO2014012025A3 (en) | Igf-1 proteins and therapeutic uses thereof | |
| PH12014501044A1 (en) | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells | |
| HK1218373A1 (zh) | 用於治療年齡相關失調的重組膠原蛋白7的給予 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BAXALTA INCORPORATED |
|
| FG | Grant or registration |